All In Biotech

Drug Trial Radar · NCT00327470

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).

Last checked: Nov 20, 2026Latest source record: Apr 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

288

Actual

Start

Jul 2006

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

Conditions

  • Age Related Macular Degeneration (AMD)
  • Macular Degeneration
  • Choroidal Neovascularization (CNV)

Interventions

  • Pegaptanib Sodium 0.3 mgDrug

    Pegaptanib Sodium dosed every 6 weeks in affected eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline Through Week 54 in Distance Visual Acuity (VA) in Subjects With Early and Established CNV LesionsTime frame: Baseline through Week 54

Locations

58 sites in 15 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Graz, Austria

  • Pfizer Investigational Site

    Innsbruck, Austria

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Liège, Belgium

  • Pfizer Investigational Site

    Victoria, British Columbia, Canada

  • Pfizer Investigational Site

    Victoria, British Columbia, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    London, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

  • Pfizer Investigational Site

    Olomouc, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Glostrup Municipality, Denmark

  • Pfizer Investigational Site

    Kuopio, Finlad, Finland

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Nancy, France

  • Pfizer Investigational Site

    Nantes, France

  • Pfizer Investigational Site

    Paris, France

  • Pfizer Investigational Site

    Paris, France

  • Pfizer Investigational Site

    Saint-Etienne, France

  • Pfizer Investigational Site

    Tours, France

  • Pfizer Investigational Site

    Dortmund, Germany

  • Pfizer Investigational Site

    Freiburg im Breisgau, Germany

  • Pfizer Investigational Site

    Halle, Germany

  • Pfizer Investigational Site

    Münster, Germany

  • Pfizer Investigational Site

    Athens, Greece

  • Pfizer Investigational Site

    Athens, Greece

  • Pfizer Investigational Site

    Ancona, Italy

  • Pfizer Investigational Site

    Bari, Italy

  • Pfizer Investigational Site

    Florence, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Gdansk, Poland

  • Pfizer Investigational Site

    Katowice, Poland

  • Pfizer Investigational Site

    Poznan, Poland

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.